ATE214613T1 - Zusammensetzungen, die einen guggul-extrakt mit phosphatsalzen enthalten - Google Patents
Zusammensetzungen, die einen guggul-extrakt mit phosphatsalzen enthaltenInfo
- Publication number
- ATE214613T1 ATE214613T1 AT99308490T AT99308490T ATE214613T1 AT E214613 T1 ATE214613 T1 AT E214613T1 AT 99308490 T AT99308490 T AT 99308490T AT 99308490 T AT99308490 T AT 99308490T AT E214613 T1 ATE214613 T1 AT E214613T1
- Authority
- AT
- Austria
- Prior art keywords
- phosphate
- guggul extract
- compositions containing
- composition
- phosphate salts
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 239000009437 guggulu extract Substances 0.000 title abstract 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 title 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 abstract 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 abstract 2
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 210000000577 adipose tissue Anatomy 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 239000001506 calcium phosphate Substances 0.000 abstract 1
- 229910000389 calcium phosphate Inorganic materials 0.000 abstract 1
- 235000011010 calcium phosphates Nutrition 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 229940089491 hydroxycitric acid Drugs 0.000 abstract 1
- 230000003516 hyperlipidaemic effect Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 230000036651 mood Effects 0.000 abstract 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 1
- 229910000160 potassium phosphate Inorganic materials 0.000 abstract 1
- 235000011009 potassium phosphates Nutrition 0.000 abstract 1
- 239000001488 sodium phosphate Substances 0.000 abstract 1
- 229910000162 sodium phosphate Inorganic materials 0.000 abstract 1
- 235000011008 sodium phosphates Nutrition 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 abstract 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 abstract 1
- 229960004441 tyrosine Drugs 0.000 abstract 1
- 238000004260 weight control Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/179,328 US6113949A (en) | 1998-10-27 | 1998-10-27 | Weight control product and method of treating hyperlipidemia and increasing vigor with said product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE214613T1 true ATE214613T1 (de) | 2002-04-15 |
Family
ID=22656113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99308490T ATE214613T1 (de) | 1998-10-27 | 1999-10-27 | Zusammensetzungen, die einen guggul-extrakt mit phosphatsalzen enthalten |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6113949A (de) |
| EP (1) | EP0997149B1 (de) |
| AT (1) | ATE214613T1 (de) |
| CA (1) | CA2267488A1 (de) |
| DE (1) | DE69901051D1 (de) |
| GB (1) | GB2343115A (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002193818A (ja) * | 2000-12-22 | 2002-07-10 | Council Scient Ind Res | ググリピッドの新規使用法:認知エンハンサー、抗高血糖性の、及び皮膚の状態に関するものとして |
| US6485710B2 (en) * | 2000-12-27 | 2002-11-26 | Arthur Zuckerman | Appetite suppressant toothpaste |
| US6610277B2 (en) * | 2000-12-27 | 2003-08-26 | Arthur Zuckerman | Appetite suppressant toothpaste |
| EP1238590A1 (de) * | 2001-03-09 | 2002-09-11 | Unilever N.V. | Nahrungsmittelprodukt auf der Basis von Fett |
| EP1390051A2 (de) | 2001-05-29 | 2004-02-25 | Unilever Plc | Lebensmittelzusammensetzungen zur verminderung der insulinresistenz |
| US6849278B2 (en) * | 2001-11-21 | 2005-02-01 | Universal Biotech Co., Ltd. | Method to counter oxidation of LDL, decrease triglyceride or cholesterol and inhibit atherosclerosis using Hibiscus sabdariffa extract |
| US6852342B2 (en) * | 2002-03-26 | 2005-02-08 | Avoca, Inc. | Compounds for altering food intake in humans |
| WO2003090673A2 (en) * | 2002-04-22 | 2003-11-06 | Rtc Research & Development, Llc. | Compositions and methods for promoting weight loss, thermogenesis, appetite suppression, lean muscle mass, increasing metabolism and boosting energy levels, and use as a dietary supplement in mammals |
| US20040018959A1 (en) * | 2002-05-02 | 2004-01-29 | Randall S. Hickle | System and methods of lipid removal from the body |
| US6565896B1 (en) * | 2002-07-03 | 2003-05-20 | Vitacost.Com, Inc. | Cholesterol treatment formulation |
| US20040253327A1 (en) * | 2003-06-12 | 2004-12-16 | Niazi Sarfaraz K. | Compositions and methods for reducing or controlling blood cholesterol, lipoproteins, triglycerides, and sugar and preventing or treating cardiovascular diseases |
| US20050025844A1 (en) * | 2003-08-02 | 2005-02-03 | Matthias Boldt | Weight control compositions and methods |
| US20050163872A1 (en) * | 2004-01-23 | 2005-07-28 | Cargill, Incorporated | Compositions and methods for reducing cholesterol |
| WO2006017211A1 (en) * | 2004-07-12 | 2006-02-16 | Research Development Foundation | Guggulsterone as an inhibitor of nuclear factor-kb and ikbalpha kinase activation |
| EP1811953B1 (de) * | 2004-10-22 | 2009-12-16 | Laboratoire Nuxe | Neuartige verwendung von chaulmoogra-öl und guggulipiden in therapeutika und kosmetika |
| FR2876912B1 (fr) * | 2004-10-25 | 2007-04-20 | Nuxe Sa Lab | Nouvelle utilisation de guggulipides en therapeutique et en cosmetique |
| US8287924B2 (en) | 2011-03-17 | 2012-10-16 | Sonia Pharma Gmbh | Treatment of menopausal symptoms as novel indication for myrrh |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4117120A (en) * | 1977-02-11 | 1978-09-26 | Elderbaum Gilbert J | Medication for herpes simplex and canker sores |
| US4364922A (en) * | 1980-10-14 | 1982-12-21 | University Of Virginia Alumni Patents Foundation | Adenosine antagonists in the treatment and diagnosis of A-V node conduction disturbances |
| US4592912A (en) * | 1983-10-31 | 1986-06-03 | Harriet Nickolaus | Ache and pain relieving and preventing composition |
| US4719111A (en) * | 1985-06-14 | 1988-01-12 | Wilson Lynn M | Novel composition for treatment of decubitus ulcers |
| US4713242A (en) * | 1985-11-07 | 1987-12-15 | Tecma Laboratories, Inc. | Skin therapeutic mixture containing eupatorium extract |
| US4847069A (en) * | 1987-10-22 | 1989-07-11 | The Procter & Gamble Company | Photoprotection compositions comprising sorbohydroxamic acid and an anti-inflammatory agent |
| US4847071A (en) * | 1987-10-22 | 1989-07-11 | The Procter & Gamble Company | Photoprotection compositions comprising tocopherol sorbate and an anti-inflammatory agent |
| US5011843A (en) * | 1988-05-31 | 1991-04-30 | Iolab Corporation | Treatment of glaucoma using phosphodiesterase inhibitors |
| DK339289D0 (da) * | 1989-07-07 | 1989-07-07 | Dak Lab As | Farmaceutisk praeparat |
| JPH0366623A (ja) * | 1989-08-03 | 1991-03-22 | Toreede Uindo Kk | 肥満防止剤及びその製造法 |
| EP0447706A1 (de) * | 1990-03-22 | 1991-09-25 | Cipla Limited | Verfahren zur Herstellung einer pharmazeutischen aktiven Mischung der Guggulsteronen Z und E |
| IT1247933B (it) * | 1991-05-15 | 1995-01-05 | Indena Spa | Estratti di commiphora mukul e loro applicazioni terapeutiche |
| US5238965A (en) * | 1991-05-31 | 1993-08-24 | The Procter & Gamble Company | Methods of using lysophosphatidic acids for regulating skin wrinkles |
| US5104676A (en) * | 1991-06-27 | 1992-04-14 | Abbott Laboratories | Weight control product |
| WO1993010756A1 (en) * | 1991-11-25 | 1993-06-10 | Richardson-Vicks, Inc. | Use of salicylic acid for regulating skin wrinkles and/or skin atrophy |
| CA2159985C (en) * | 1993-04-20 | 1999-07-13 | Raphael Warren | Methods of using hesperetin for sebum control and treatment of acne |
| US5494668A (en) * | 1994-07-11 | 1996-02-27 | Patwardhan; Bhushan | Method of treating musculoskeletal disease and a novel composition therefor |
| JP3396542B2 (ja) * | 1994-07-22 | 2003-04-14 | 株式会社成幸社 | 固形上の痩身用食品 |
| US5690948A (en) * | 1997-01-10 | 1997-11-25 | Elizabeth Arden Co., Division Of Conopco, Inc. | Antisebum and antioxidant compositions containing guguliped and alcoholic fraction thereof |
-
1998
- 1998-10-27 US US09/179,328 patent/US6113949A/en not_active Expired - Lifetime
-
1999
- 1999-03-29 GB GB9907037A patent/GB2343115A/en not_active Withdrawn
- 1999-03-30 CA CA002267488A patent/CA2267488A1/en not_active Abandoned
- 1999-10-27 DE DE69901051T patent/DE69901051D1/de not_active Expired - Lifetime
- 1999-10-27 EP EP99308490A patent/EP0997149B1/de not_active Expired - Lifetime
- 1999-10-27 AT AT99308490T patent/ATE214613T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0997149A1 (de) | 2000-05-03 |
| CA2267488A1 (en) | 2000-04-27 |
| EP0997149B1 (de) | 2002-03-20 |
| GB2343115A (en) | 2000-05-03 |
| GB9907037D0 (en) | 1999-05-19 |
| US6113949A (en) | 2000-09-05 |
| DE69901051D1 (de) | 2002-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69901051D1 (de) | Zusammensetzungen, die einen Guggul-Extrakt mit Phosphatsalzen enthalten | |
| Harker et al. | Interruption of vascular thrombus formation and vascular lesion formation by dietary n-3 fatty acids in fish oil in nonhuman primates. | |
| Basu et al. | Intestinal absorption in health and disease: micronutrients | |
| Felsenfeld et al. | Phosphorus, regulation of plasma calcium, and secondary hyperparathyroidism: a hypothesis to integrate a historical and modern perspective | |
| CA2229077A1 (en) | Lipid metabolism improving agent | |
| WO2002002190A3 (en) | Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes | |
| DE69122099D1 (de) | Zusammensetzung und verfahren zur prävention und behandlung von hypercholesterinämie und zellproliferationsstorungen | |
| ATE254404T1 (de) | Mehrteiliges nahrungsmittel, verfahren zu dessen herstellung und verwendung desselben | |
| NZ541593A (en) | Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis | |
| ATE129894T1 (de) | Kurzbettige, einfach ungesättigte fettsäuren enthaltende nahrungsmittel und pharmazeutische zusammensetzungen sowie deren anwendungen. | |
| Fullmer | Intestinal calcium and lead absorption: effects of dietary lead and calcium | |
| CA2078019A1 (en) | Substance or composition and uses thereof | |
| Nair et al. | Impact evaluation of iron & iodine fortified salt | |
| AU2002224240A1 (en) | Colostrum-based composition | |
| MY134314A (en) | Alertness bar | |
| ES2163472T3 (es) | Caseinas micelarias fluoradas. | |
| BG100911A (en) | Biophosphonic acids-sontaining wet-granulated form | |
| ATE413179T1 (de) | Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden | |
| JP2020528888A (ja) | 心血管器官の病態の予防及び処置における使用のための組成物 | |
| KR970702291A (ko) | 에퀼린의 산 이성질화체로부터 제조된 에퀼린 이중결합 이성질체(Anequilin double bond isomer from the acid isomerization of equilin) | |
| BRPI0309421A8 (pt) | Método de preparar um gênero alimentício e composição para tratar ou prevenir hipercolesterolemia | |
| ID27765A (id) | Plester gel yang mengandung steroid dan proses pembuatannya | |
| WO2001005356A3 (en) | Weight control product comprising a synergistic mixture of guggul extract, phosphate salt and metabolic stimulant | |
| AU1300001A (en) | Gastroresistant tablets for alimentary, dietetic and therapeutic use | |
| BR9914644A (pt) | Composições tamponadas para diálise |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |